Moreover, using the same cutoff of 1%, we found that ICB-treated HCC patients with high LAG-3+ cell proportions in the tumor microenvironment had significantly longer PFS and OS, compared to patients with low LAG-3+ cell proportions. This evidence concerns the gene LAG3 and hepatocellular carcinoma.